SomnoMed (SOM) Fundamentals 2026 — Revenue Analysis | SniperIQ
SomnoMed (SOM) is a AU-listed Healthcare company in Medical - Devices with a market capitalization of A
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SomnoMed's market cap?
SomnoMed (SOM) has a market capitalization of approximately A
What is SomnoMed's P/E ratio?
SomnoMed's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SomnoMed?
SomnoMed runs a net profit margin of -2.2%, a gross margin of 57.4%, and an operating margin of 2.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SomnoMed generate?
SomnoMed reported revenue of A
Does SomnoMed pay a dividend?
SomnoMed does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is SomnoMed financially healthy?
SomnoMed carries a debt-to-equity ratio of 0.28x and a current ratio of 1.76x, with a market beta of 0.81. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SomnoMed a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SomnoMed (SOM) the key facts are: market cap A
Track SomnoMed's full fundamentals live
Get SomnoMed's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.